Unknown

Dataset Information

0

Development of ciclesonide analogues that block SARS-CoV-2 RNA replication.


ABSTRACT: Ciclesonide is an inhaled corticosteroid used to treat asthma and is currently undergoing clinical trials for treatment of coronavirus disease 2019 (COVID-19). An active metabolite of ciclesonide, Cic2, was recently reported to repress severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) genomic RNA replication. Herein, we designed and synthesized a few types of ciclesonide analogues. Cic4 (bearing an azide group) and Cic6 (bearing a chloro group) potently decreased SARS-CoV-2 viral replication and had low cytotoxicity compared with Cic2 (bearing a hydroxy group). These compounds are promising as novel therapeutic agents for COVID-19 that show significant antiviral activity.

SUBMITTER: Tsuji G 

PROVIDER: S-EPMC8055493 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC9014634 | biostudies-literature
| S-EPMC7737752 | biostudies-literature
| S-EPMC7293530 | biostudies-literature
| S-EPMC10377386 | biostudies-literature
| S-EPMC9915467 | biostudies-literature
| S-EPMC8061462 | biostudies-literature
| S-EPMC8402726 | biostudies-literature
| S-EPMC7883726 | biostudies-literature
| S-EPMC7982646 | biostudies-literature
| S-EPMC7242921 | biostudies-literature